FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PhotoCure ASA's Free Cash Flow for the
three
months ended in Mar. 2026 was kr-6.6 Mil. PhotoCure ASA's Revenue for the
three
months ended in Mar. 2026 was kr264.6 Mil. Therefore, PhotoCure ASA's FCF Margin % for the quarter that ended in Mar. 2026 was -2.51%.
The historical rank and industry rank for PhotoCure ASA's FCF Margin % or its related term are showing as below:
OSL:PHO'
s FCF Margin % Range Over the Past 10 Years
Min: -27.95 Med: 3.66 Max: 12.43
Current: -0.45
During the past 13 years, the highest FCF Margin % of PhotoCure ASA was 12.43%. The lowest was -27.95%. And the median was 3.66%.
OSL:PHO's FCF Margin % is ranked worse than 58.77% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs OSL:PHO: -0.45
PhotoCure ASA FCF Margin % Related Terms
PhotoCure ASA FCF Margin % Historical Data
* Premium members only.
The historical data trend for PhotoCure ASA's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:PHO vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's FCF Margin % distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhotoCure ASA (OSL:PHO) has a FCF Margin % of -2.51% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PhotoCure ASA and its competitors. According to the industry distribution chart, PhotoCure ASA ranks #563 out of 958 companies in the Drug Manufacturers industry, placing it in the top 58.8%.
Is PhotoCure ASA's FCF Margin % too high?
PhotoCure ASA's current FCF Margin % is -2.51%. Based on the distribution chart, PhotoCure ASA ranks #563 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PhotoCure ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #563 out of 958 companies for FCF Margin %. This places PhotoCure ASA in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PhotoCure ASA and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current FCF Margin % is -2.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (OSL:PHO) is currently considered Modestly Undervalued. The stock's GF Value™ is kr74.44, compared to a current price of kr59.80 — trading 19.7% below its estimated fair value. The current FCF Margin % is -2.51%. PhotoCure ASA's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For PhotoCure ASA (OSL:PHO), the current FCF Margin % is -2.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (OSL:PHO) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of kr59.80 is trading 19.7% below its estimated GF Value™ of kr74.44.
GuruFocus considers PhotoCure ASA to be Modestly Undervalued.
Key valuation signals for OSL:PHO:
FCF Margin %: -2.51%
GF Value™: kr74.44 vs. price of kr59.80 (19.7% below fair value)
No single metric tells the full story. See the OSL:PHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
77GF Score
Get the complete analysis for OSL:PHO
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:PHO has been successfully added to your 
